The global cell line development market was estimated to be USD 5.29 billion in 2023 and is expected to reach at USD 14.82 billion by 2034 with a CAGR of 9.82% during the forecast period 2024-2034. Rise in advanced technologies for manufacturing new cell lines, rising demand for monoclonal antibodies & cancer treatments, expanding biopharmaceutical sector, increasing number of research & development initiatives focused on biosimilars & biologic products, growing requirement for innovative pharmaceuticals, vaccines, biosimilars, & therapeutic proteins, increasing prevalence of chronic diseases such as cancer, the acceptance of novel biopharmaceutical drugs, and surge in the introduction of innovative products for cell line development are some of the key factors boosting the market growth.
Surge in the introduction of innovative products for cell line development is predicted to boost the market growth during the forecast period. The process of cell line development and authentication is both expensive and intricate, demanding a range of expertise across different disciplines. Given their pivotal role in drug discovery and development, it's crucial to thoroughly test and validate cell lines to prevent misidentification, detect contaminants or harmful microorganisms, monitor genetic stability, and ensure the accuracy of experimental research. As a result, pharmaceutical developers are increasingly turning to specialized service providers with the necessary equipment and expertise to address the technical and operational hurdles. For instance, in June 2023, Matica Bio has unveiled MatiMax HEK293 and HEK293T cell lines to expedite the advancement of cell and gene therapies. These cell lines boost doubling times, enhance transfection efficiencies, and augment production capacity.
By product, reagents & media was the highest revenue-grossing segment in the global cell line development market in 2023 owing to its extensive utility spans various fields including bioproduction, regenerative medicine, tissue engineering, drug discovery, and toxicity testing. Reagents and media are integral elements of the cell culture and cell line development process, and they entail substantial costs. Additionally, services is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for monoclonal antibodies, patent expiration of major biologic drugs, growing need for efficient cancer treatments, advancements in cell line development technology, increase in the outsourcing of biologics production, rising approvals for both biologics and biosimilars, and collaborations among market players. For instance, in June 2023, Thermo Fisher Scientific has partnered with Celltrio to combine Celltrio's RoboCell cell line automation platform with Thermo Fisher Scientific's cell line workflow software. This collaboration aims to meet the demand for high-throughput automated cell line development in Europe.
By source, mammalian cell line was the highest revenue-grossing segment in the global cell line development market in 2023 as they are extensively used for producing monoclonal antibodies, vaccines, and biologics because of their enhanced capacity for complex protein expression and the proliferation of new product introductions. For instance, in January 2023, Berkeley Lights, Inc., a company specializing in life science tools, has introduced Beacon Select, its latest optofluidic system designed for cell line development (CLD). Additionally, non-mammalian cell line is predicted to grow at the fastest CAGR during the forecast period owing to the growing research & development activities, and surge in approvals by regulatory authorities.
By type of cell line, recombinant cell lines was the highest revenue-grossing segment in the global cell line development market in 2023 owing to its widespread application in biologics manufacturing processes, gene activation, & protein interactions, growing demand for drug screening and toxicity testing, increasing adoption of recombinant proteins, and rising need for biologics to address cancer and autoimmune diseases. Additionally, hybridomas is predicted to grow at the fastest CAGR during the forecast period owing to the benefits it offers, including continuous growth, fusion of diverse cell types, and large-scale production of pure antibodies. hybridoma technology continues to progress, with advancements such as employing feeder layers containing murine peritoneal cells and macrophages from mice. A noticeable increase in collaborations among industry stakeholders. For instance, in June 2023, Curia has entered into a licensing agreement with MilliporeSigma to utilize the CHOZN GS cell line technology from the latter company for the production of therapeutic proteins and antibodies.
By application, bioproduction was the highest revenue-grossing segment in the global cell line development market in 2023 owing to the rise in demand for drug and vaccine manufacturing, increase in viral and communicable diseases, as well as the introduction of new medications. Bioproduction technology encompasses the manufacturing of biologics-based treatments, including vaccines, therapeutic proteins, cell therapies, and gene therapies. For instance, in November 2022, Lonza has unveiled an innovative capsule solution called Capsugel Enprotect for enteric (intestinal) drug delivery. These capsules exclusively release their contents in the intestine without disintegrating during stomach transit. Capsugel Enprotect capsules streamline drug product manufacturing by eliminating the need for additional coating or sealing processes. Additionally, tissue engineering is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend in the utilization of tissue engineering for patient treatment, including procedures such as bladder implants, skin grafts, trachea repairs, small artery implantations, & cartilage replacements, and rising recognition of personalized medicine and regenerative therapies, which involve the safe laboratory cultivation of tissues or organs using cell culture techniques.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing use of cell culture techniques is driven by their cost-effectiveness, high productivity, the availability of advanced healthcare infrastructure, rising demand for biologics, increasing awareness of cell therapy, high healthcare expenditure and expanding partnerships among industry leaders. For instance, in June 2023, Synthego has entered into a partnership with American Type Culture Collection (ATCC) to integrate Synthego's CRISPR gene-editing proficiency with ATCC's mammalian and mouse cell lines. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the untapped opportunities present alongside enhancements in healthcare infrastructure, as well as favorable initiatives by government and manufacturers within the biotechnology sector, and increase in the production of vaccines, therapeutic proteins, and other biotechnological products. For instance, in May 2023, Scientists at FUJIFILM Diosynth Biotechnologies have improved their techniques for developing cell lines by employing Cyto-Mine, which is a next-generation single-cell analysis device developed by Sphere Fluidics.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Surge in the introduction of innovative products for cell line development is predicted to boost the market growth during the forecast period. The process of cell line development and authentication is both expensive and intricate, demanding a range of expertise across different disciplines. Given their pivotal role in drug discovery and development, it's crucial to thoroughly test and validate cell lines to prevent misidentification, detect contaminants or harmful microorganisms, monitor genetic stability, and ensure the accuracy of experimental research. As a result, pharmaceutical developers are increasingly turning to specialized service providers with the necessary equipment and expertise to address the technical and operational hurdles. For instance, in June 2023, Matica Bio has unveiled MatiMax HEK293 and HEK293T cell lines to expedite the advancement of cell and gene therapies. These cell lines boost doubling times, enhance transfection efficiencies, and augment production capacity.
By product, reagents & media was the highest revenue-grossing segment in the global cell line development market in 2023 owing to its extensive utility spans various fields including bioproduction, regenerative medicine, tissue engineering, drug discovery, and toxicity testing. Reagents and media are integral elements of the cell culture and cell line development process, and they entail substantial costs. Additionally, services is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for monoclonal antibodies, patent expiration of major biologic drugs, growing need for efficient cancer treatments, advancements in cell line development technology, increase in the outsourcing of biologics production, rising approvals for both biologics and biosimilars, and collaborations among market players. For instance, in June 2023, Thermo Fisher Scientific has partnered with Celltrio to combine Celltrio's RoboCell cell line automation platform with Thermo Fisher Scientific's cell line workflow software. This collaboration aims to meet the demand for high-throughput automated cell line development in Europe.
By source, mammalian cell line was the highest revenue-grossing segment in the global cell line development market in 2023 as they are extensively used for producing monoclonal antibodies, vaccines, and biologics because of their enhanced capacity for complex protein expression and the proliferation of new product introductions. For instance, in January 2023, Berkeley Lights, Inc., a company specializing in life science tools, has introduced Beacon Select, its latest optofluidic system designed for cell line development (CLD). Additionally, non-mammalian cell line is predicted to grow at the fastest CAGR during the forecast period owing to the growing research & development activities, and surge in approvals by regulatory authorities.
By type of cell line, recombinant cell lines was the highest revenue-grossing segment in the global cell line development market in 2023 owing to its widespread application in biologics manufacturing processes, gene activation, & protein interactions, growing demand for drug screening and toxicity testing, increasing adoption of recombinant proteins, and rising need for biologics to address cancer and autoimmune diseases. Additionally, hybridomas is predicted to grow at the fastest CAGR during the forecast period owing to the benefits it offers, including continuous growth, fusion of diverse cell types, and large-scale production of pure antibodies. hybridoma technology continues to progress, with advancements such as employing feeder layers containing murine peritoneal cells and macrophages from mice. A noticeable increase in collaborations among industry stakeholders. For instance, in June 2023, Curia has entered into a licensing agreement with MilliporeSigma to utilize the CHOZN GS cell line technology from the latter company for the production of therapeutic proteins and antibodies.
By application, bioproduction was the highest revenue-grossing segment in the global cell line development market in 2023 owing to the rise in demand for drug and vaccine manufacturing, increase in viral and communicable diseases, as well as the introduction of new medications. Bioproduction technology encompasses the manufacturing of biologics-based treatments, including vaccines, therapeutic proteins, cell therapies, and gene therapies. For instance, in November 2022, Lonza has unveiled an innovative capsule solution called Capsugel Enprotect for enteric (intestinal) drug delivery. These capsules exclusively release their contents in the intestine without disintegrating during stomach transit. Capsugel Enprotect capsules streamline drug product manufacturing by eliminating the need for additional coating or sealing processes. Additionally, tissue engineering is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend in the utilization of tissue engineering for patient treatment, including procedures such as bladder implants, skin grafts, trachea repairs, small artery implantations, & cartilage replacements, and rising recognition of personalized medicine and regenerative therapies, which involve the safe laboratory cultivation of tissues or organs using cell culture techniques.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing use of cell culture techniques is driven by their cost-effectiveness, high productivity, the availability of advanced healthcare infrastructure, rising demand for biologics, increasing awareness of cell therapy, high healthcare expenditure and expanding partnerships among industry leaders. For instance, in June 2023, Synthego has entered into a partnership with American Type Culture Collection (ATCC) to integrate Synthego's CRISPR gene-editing proficiency with ATCC's mammalian and mouse cell lines. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the untapped opportunities present alongside enhancements in healthcare infrastructure, as well as favorable initiatives by government and manufacturers within the biotechnology sector, and increase in the production of vaccines, therapeutic proteins, and other biotechnological products. For instance, in May 2023, Scientists at FUJIFILM Diosynth Biotechnologies have improved their techniques for developing cell lines by employing Cyto-Mine, which is a next-generation single-cell analysis device developed by Sphere Fluidics.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Source, Type Of Cell Line, and Application
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Cell Line Development Market Report 2023 - 2034
Cell Line Development Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Services
- Reagents And Media
- Accessories And Consumables
- Equipment
- Bioreactors
- Centrifuges
- Storage Equipment
- Automated Systems
- Others
Cell Line Development Market Analysis & Forecast by Source 2023 - 2034 (Revenue USD Bn)
- Mammalian Cell Line
- Non-Mammalian Cell Line
- Amphibians
- Insects
Cell Line Development Market Analysis & Forecast by Type Of Cell Line 2023 - 2034 (Revenue USD Bn)
- Continuous Cell Lines
- Recombinant Cell Lines
- Primary Cell Lines
- Hybridomas
Cell Line Development Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Toxicity Testing
- Drug Discovery
- Bioproduction
- Tissue Engineering
- Others
Cell Line Development Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cell Line Development Market: Product Estimates & Trend Analysis
8. Cell Line Development Market: Source Estimates & Trend Analysis
9. Cell Line Development Market: Type Of Cell Line Estimates & Trend Analysis
10. Cell Line Development Market: Application Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Cell Line Development Market
13. Europe Global Cell Line Development Market
14. Asia Pacific Global Cell Line Development Market
15. Latin America Global Cell Line Development Market
16. MEA Global Cell Line Development Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Merck KGaACorning Inc.
- Danaher
- Berkeley Lights
- Creative BioLabs.
- Lonza
- Sartorius AG
- Thermo Fisher Scientific Inc.
- WuXi PharmaTech
- Advanced Instruments
